Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2389 in Liver Fibrosis and Compensated Cirrhosis
NCT06750276Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of AZD2389 in Liver Fibrosis (LF), Liver cirrhosis (LC), metabolic dysfunction-associated steatohepatitis (MASH), steatotic liver disease (MASLD), sponsored by AstraZeneca. Started Dec 2024; status: completed.
02
Drugs
AZD2389
03
Conditions
Liver Fibrosis (LF)Liver cirrhosis (LC)metabolic dysfunction-associated steatohepatitis (MASH)steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT06750276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06750276.